Hengrui pharmaceutical hydrochloric acid right metomide injection was evaluated by generic consistency

January 20, Hengrui Pharmaceuticals announced that recently received the State Drug Administration approved the issuance of the "drug supplement application approval notice" on hydrochloric acid right metomide injection, the company's hydrochloric acid right metomide injection through generic drug consistency evaluation.
hydrochloric acid right metomy is a relatively selective alpha2-epinephrine-perder agonist suitable for sedation during tracheal intination and mechanical ventilation in surgical patients undergoing general anaesthetic, for starting intestion during intensive care and sedation in patients using ventilators.
hydrochloric acid right metomide injection was developed jointly by Oricon Pharma and Abbott and was first approved by the FDA in December 1999 under the name Frontex ®.
follow-up in the European Union, Japan and other countries and regions listed for sale.
Division I in 2009 took the lead in the domestic listing of hydrochloric acid right metomide injection, the trademark is Abein ®, so far, in addition to the company, the domestic Sichuan Guorui, Hunan Colum, Yichang Renfu and other 11 enterprises have been approved for production, including Yangzijiang Pharmaceuticals, China Pharmaceutical Group Industry Co., Ltd. Langfang Branch 2 equivalent to through generic pharmaceutical consistency evaluation.
other Zhengda Qing, Fu'an Pharmaceuticals and other declared production, did not see the approved information.
the Evaluate Pharma database, the global sales of hydrochloric acid right metomide injections in 2019 are approximately $419 million.
, the company has invested approximately RMB 6.79 million in research and development on the generics consistency evaluation project.